Short Interest in Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) Grows By 195.2%

Posted by Amy Steele on May 30th, 2026

Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR – Get Free Report) saw a large growth in short interest during the month of May. As of May 15th, there was short interest totaling 278,140 shares, a growth of 195.2% from the April 30th total of 94,217 shares. Currently, 1.3% of the shares of the company are sold short. Based on an average daily volume of 1,597,098 shares, the short-interest ratio is presently 0.2 days.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cuprina Holdings (Cayman) in a research note on Friday, April 24th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Get Our Latest Stock Report on CUPR

Cuprina Holdings (Cayman) Stock Down 27.7%

Shares of Cuprina Holdings (Cayman) stock traded down $0.92 during trading on Friday, hitting $2.39. 292,379 shares of the stock were exchanged, compared to its average volume of 283,651. The stock has a fifty day moving average of $2.53. Cuprina Holdings has a 1-year low of $1.76 and a 1-year high of $76.00. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.35 and a quick ratio of 2.35.

Cuprina Holdings (Cayman) (NASDAQ:CUPR – Get Free Report) last announced its quarterly earnings results on Monday, April 27th. The company reported ($0.40) EPS for the quarter. The company had revenue of $0.01 million for the quarter.

Cuprina Holdings (Cayman) Company Profile

(Get Free Report)

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. We believe we will be able to build upon and leverage such expertise to develop innovative cosmeceutical products in the future.